Covid19, Healthy
Conditions
Keywords
Vaccine, DNA
Brief summary
Phase I study of the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 (COVID-19)
Detailed description
This Phase I, randomized, placebo-controlled, dose-ranging, single-blind study will assess the safety, tolerability, and immunogenicity of GLS-5310 DNA vaccine administered intradermally (ID) with or without concomitant intranasal (IN) administration of GLS-5310. Vaccine delivered ID will either be performed by Mantoux injection and followed by suction applied to the skin surface using the Gene-Derm device or Mantous injection alone without applied suction. Vaccine delivered IN will be administered using the MAD300 atomizer.
Interventions
BIOLOGICALGLS-5130
GLS-5310 DNA plasmid vaccine
BIOLOGICALPlacebo
Placebo
Sponsors
GeneOne Life Science, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 18 to 65 years of age 2. Able to provide informed consent 3. Able and willing to comply with study procedures 4. For women of childbearing potential, able and willing to use an approved form of pregnancy prevention during the study 5. Negative test result for the presence of SARS-CoV-2 IgM and IgG antibodies, which indicate recent or prior infection
Exclusion criteria
1. Persons involved in the care of patients with COVID-19 and health care workers considered, in the opinion of the investigator, to be at increased risk of infection from SARS-CoV-2 2. Persons with symptoms in the past 2 weeks consistent with possible acute SARS-CoV-2 infection to include fever, loss of smell or taste 3. Persons diagnosis of type 2 diabetes mellitus 4. Persons with a diagnosis of chronic kidney disease 5. Persons with a diagnosis of chronic obstructive pulmonary disease (COPD) 6. Persons with a diagnosis of heart conditions to include heart failure, coronary artery disease, prior heart attack, cardiomyopathy 7. Obesity (BMI of 30 kg/m2 or greater) 8. Sickle cell disease 9. Current or former smoker 10. Current or planned pregnancy during the study 11. Currently breastfeeding 12. Current or past participation in a coronavirus (MERS-CoV, SARS-CoV-2) vaccine study, or receipt of a SARS-CoV-2 vaccine that has been approved by the FDA, including vaccines that have received Emergency Use Authorization (EUA) 13. Administration of an investigational agent within 90 days of the 1st dose 14. Administration of a vaccine within 2 weeks prior to the 1st dose 15. Administration of immune globulin within 6 months of enrollment 16. Administration of an anti-TNFα inhibitor such as infliximab, adalimumab, etanercept, or anti-CD20 monoclonal antibody rituximab within 6 months from enrollment 17. Current daily treatment of systemic corticosteroids of 20 mg of prednisone or greater; or the equivalent dose of other systemic corticosteroids 18. Treatment within the four weeks prior to enrollment with any drug intended for the prophylaxis or treatment of COVID-19 19. Any prior treatment with an anti-SARS-CoV-2 monoclonal antibody or immune serum 20. Prior treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal antibody, or anti-JAK inhibitor (see Appendix B exclusionary period for specific drugs) 21. History of malignancy 22. History of transplantation (any organ or bone marrow) 23. Current or planned chemotherapy treatment for hematologic or solid tumor during study period 24. History of other congenital or acquired immunodeficiency, excluding those with HIV infection who are taking highly active antiretroviral therapy and who have documentation of undetectable serum viral load 25. History of PCR-confirmed infection with SARS-CoV-2 26. Not willing to allow storage and future use of samples for SARS-CoV-2 related research and who have a CD4 count \> 200 cells/µL on two measures at least 3 months apart 27. Prisoner or subjects who are compulsorily detained for treatment of a psychiatric illness 28. Any illness or condition that, in the opinion of the investigator, may affect the safety of the subject or the evaluation of a study endpoint
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | Through 56 weeks post vaccination | solicited/unsolicited local and systemic AEs |
| Geometric mean titer (GMT) of antigen specific antibody titers | Through 56 weeks post vaccination | Endpoint titer of binding antibody in serum |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of positive response rate of T cell responses induced by GLS-5310 | Through 56 weeks post vaccination | T-cell response of antigen-specific interferon - gamma (IFN-γ) secretion in PBMC at each timepoint |
| Geometric mean titer (GMT) of neutralizing antibody titers | Through 56 weeks post vaccination | Plaque-reduction neutralizing titer(PRNT) in serum at each timepoint |
Other
| Measure | Time frame | Description |
|---|---|---|
| Determine IgA antibody responses following vaccination of GLS-5310 related to treatment arm | Through 56 weeks post vaccination | — |
| Determine IgG antibody responses after a single dose of GLS-5310 related to treatment arm | Through 56 weeks post vaccination | Endpoint titer of binding antibody in serum at each timepoint |
Countries
Puerto Rico
Contacts
Primary ContactMedical Monitor
Backup ContactProject Manager
Outcome results
None listed